The present study tested the hypothesis that cantharidin abrogates feedback STAT3 activation induced by EGFR inhibition in osteosarcoma, resulting in enhanced tumor suppression upon combined SC and erlotinib treatment. This evidence concerns the gene EGFR and neoplasm.